A Chip Stock Gets Checked - Behind the Drop in Intel; and Gilead’s Remdesivir Gets the Green Light
Publisher |
CNBC
Media Type |
audio
Categories Via RSS |
Business
Investing
News
Publication Date |
Oct 22, 2020
Episode Duration |
00:43:53

Intel shares plunged after the company reported weak results for its data center group. What’s next for the stock that’s been far underperforming the rest of the semi sector. And Gilead gets FDA approval for remdesivir. We break down the rest of the race for a COVID vaccine.

This episode currently has no reviews.

Submit Review
This episode could use a review!

This episode could use a review! Have anything to say about it? Share your thoughts using the button below.

Submit Review